Rheumatology

Lung Cancer

Questions discussed in this category

Do you use immune checkpoint inhibitors in NSCLC patients with pre-existing, well-controlled autoimmune disease?

Does the type of autoimmune disease (ex IBD, rheumatoid arthritis, interstitial lung disease) matter?

2 Answers available

What is your approach for an RA patient with lung cancer who is starting immunotherapy?

1 Answer available

How would you treat active rheumatoid arthritis in a patient in complete response on loralatinib for stage IV ALK positive NSCLC?

Patient already on methotrexate and plaquenil.

1 Answer available

What is the appropriate management of severe myalgia during atezolizumab infusion?

1 Answer available

Papers discussed in this category

Nature reviews. Rheumatology, 2022 Oct 05

Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases.

Oncoimmunology, 2023 Oct 30

Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases.

J Clin Oncol, 2021 Dec 20

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.

J Natl Compr Canc Netw,

Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.

J Immunother Cancer, 2021 Jun

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.

Ann Oncol, 2022 Oct 18

Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Related Topics in Rheumatology